Moreover, the clinical response and remission rates were similar to the results obtained in two RCT mentioned above, ATTAIN and ARRIVE, which examined RA patients with inadequate response to anti-TNF-alpha. The gene discussed is TNF; the disease is rheumatoid arthritis.